In the EU, rare diseases that are also life-threatening or chronically debilitating with a low prevalence and a high level of complexity are defined as orphan diseases.
Some 20-30 million Europeans are affected by rare diseases.
The European biotech industry is calling for a robust and transparent framework in which HTA woul
From diagnosis to treatment and in terms of medicines manufactured, healthcare biotechnology is a
Biotechnology provides powerful tools to develop diagnostics and treatments for orphan diseases.